Ardsley Advisory Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
PF
Ardsley Advisory Partners's XBI Position: Q1 2023 in Review
Ardsley Advisory Partners sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2023, closing a stake of 110,450 shares — an estimated $9.19M sold.
Ardsley Advisory Partners first reported a position in XBI in Q1 2014 and held it in 23 quarters. The position peaked at $23.5M in Q4 2017. 713 funds tracked by Wall St. Rank hold XBI as of Q1 2023.
- Ardsley Advisory Partners reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2023 after selling out during the quarter.
- Ardsley Advisory Partners sold 110,450 State Street SPDR S&P Biotech ETF shares in Q1 2023, an estimated $9.19M.
- Ardsley Advisory Partners first reported a position in State Street SPDR S&P Biotech ETF in Q1 2014 and held it in 23 quarters.
- Ardsley Advisory Partners's State Street SPDR S&P Biotech ETF position peaked at $23.5M in Q4 2017.
- 713 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2023.
Based on Ardsley Advisory Partners's 13F filing for Q1 2023, filed 15 May 2023.